Non-anticoagulant heparin derivatives for COVID-19 treatment

Area of Science:

• Biochemistry
• Virology
• Pharmacology

Background:

• COVID-19 (coronavirus disease 2019), caused by SARS-CoV-2, triggers severe inflammatory responses, particularly in the lungs and kidneys.
• Exogenous heparin has demonstrated potential in mitigating COVID-19 severity through anticoagulant and non-anticoagulant pathways.
• Known heparin drawbacks include structure-activity relationship complexities, contamination risks, and anticoagulant side effects.

Purpose of the Study:

• To explore the therapeutic potential of heparin and its derivatives in managing COVID-19.
• To address the limitations and side effects associated with conventional heparin therapy.
• To investigate non-anticoagulant heparin derivatives as targeted treatments for COVID-19 and other inflammatory conditions.

Main Methods:

• Review of existing evidence on heparin's mechanisms of action in COVID-19.
• Detailed analysis of heparin therapy's drawbacks, including anticoagulant activity and structure-activity relationships.
• Consideration of chemically modified and enzymatically depolymerized heparin derivatives.

Main Results:

• Heparin exhibits multiple non-anticoagulant mechanisms beneficial against COVID-19, such as heparanase inhibition and viral entry blocking.
• Heparin therapy presents significant drawbacks, including potential contamination and undesirable anticoagulant effects.
• Non-anticoagulant heparin derivatives show promise for targeted antiviral and anti-inflammatory effects.

Conclusions:

• Targeting non-anticoagulant mechanisms of heparin offers a promising therapeutic strategy for COVID-19.
• Development of specific non-anticoagulant heparin derivatives could overcome the limitations of traditional heparin therapy.
• Further research into structure-activity relationships of heparin derivatives is crucial for optimizing treatments for COVID-19 and inflammatory disorders.